Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 8:35 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Silence Therapeutics focuses on siRNA therapeutics for diseases with unmet medical needs, including cardiovascular risk and iron-loading anemias, leveraging its proprietary mRNAi GOLD™ platform. The company collaborates with AstraZeneca and others to further its research.

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

12 May 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the Company will participate in a fireside chat at the virtual RBC Capital Markets Global Healthcare Conference on Wednesday, May 19^th at 8:35 a.m. ET / 1:35 p.m. BST

A live webcast of the presentation can be accessed via the Investors section of Silence’s website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company's website following the conference.

Enquiries:

Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com	Tel:  +1 (646) 637-3208
Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence	Tel:  +44 (0) 20 7597 5970
European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com	Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

FAQ

When is Silence Therapeutics participating in the RBC Capital Markets Global Healthcare Conference?

Silence Therapeutics will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 8:35 a.m. ET.

How can I access the Silence Therapeutics conference presentation?

The presentation can be accessed via a live webcast on Silence Therapeutics' Investors section of their website.

What is the focus of Silence Therapeutics' therapeutic development?

Silence Therapeutics focuses on developing siRNA therapeutics to treat diseases with significant unmet medical needs.

What is the ticker symbol for Silence Therapeutics?

The ticker symbol for Silence Therapeutics is SLN, listed on both AIM and Nasdaq.

What collaborations does Silence Therapeutics have?

Silence Therapeutics collaborates with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda in its research and development efforts.